19 healthcare orgs join Surescripts network

Surescripts is adding 19 state health information exchanges (HIEs) and health information service providers (HISPs) to its network. The new connections will facilitate clinical data sharing across local and regional care communities for improved care coordination, according to its Aug. 13 announcement. The network supports Direct and other security standards and initiatives.

“The continued growth of the Surescripts network is driven by the fact that healthcare communities are realizing that electronic health information exchange is necessary to transform the way healthcare is delivered at the patient level and the increasingly rapid implementation of the federal government’s Meaningful Use guidelines,” said Harry Totonis, president and chief executive officer of Surescripts, in the announcement.

New participants include:

  • Cerner Corporation
  • Chesapeake Regional Information System for Our Patients (Maryland HIE)
  • CliniSync (Ohio Health Information Partnership)
  • Colorado Regional Health Information Organization
  • Great Lakes HIE (Michigan)
  • Greater Rochester Regional Health Information Organization (New York)
  • HealtheConnections RHIO Central NY
  • HealthInfoNet (Maine HIE)
  • Illinois HIE (ILHIE)
  • Informatics Corporation of America (Tennessee HISP)
  • Iowa HIE
  • Keystone Health Information Exchange (KeyHIE)
  • MaxMD (New Jersey HIE)
  • Michigan Health Connect
  • Michigan Health Information Network Shared Services (MiHIN)
  • Quest Diagnostics
  • University of Pittsburgh Medical Center
  • HEALTHeLINK (WNY RHIO)
  • West Virginia Health Information Network

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.